Extragonadal seminoma
disease diseaseOn this page
Also known as extragonadal primary seminomaprimary extragonadal seminoma
Summary
Extragonadal seminoma (MONDO:0003668) is a disease and 4 clinical trials. Top therapeutic interventions include etoposide phosphate, ifosfamide, and palbociclib. A subtype of seminoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 4
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | extragonadal seminoma |
| Mondo ID | MONDO:0003668 |
| DOID | DOID:5838 |
| NCIT | C7327 |
| UMLS | C1333502 |
| MedGen | 234243 |
| GARD | 0023613 |
| Is cancer (heuristic) | no |
Also known as: extragonadal primary seminoma · extragonadal seminoma · primary extragonadal seminoma
Disease family
This is a subtype of seminoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › malignant germ cell tumor › seminoma › extragonadal seminoma
Related subtypes (1): testicular seminoma
Subtypes (1): mediastinum seminoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 4.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 3 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02375204 | PHASE3 | ACTIVE_NOT_RECRUITING | Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors |
| NCT00957905 | PHASE2 | COMPLETED | Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors |
| NCT01037790 | PHASE2 | COMPLETED | Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer |
| NCT01808534 | PHASE2 | TERMINATED | Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| ETOPOSIDE PHOSPHATE | 4 | 1 |
| IFOSFAMIDE | 4 | 1 |
| PALBOCICLIB | 4 | 1 |
| PALIFOSFAMIDE | 3 | 1 |
| ALVOCIDIB HYDROCHLORIDE | 2 | 1 |